# A Study to Evaluate the Effects of a Single and Multiple Oral Doses of GLPG3121 in Adult, Healthy, Male Subjects

> **NCT03899909** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 31 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GLPG3121 SAD
- **DRUG:** Placebo SAD
- **DRUG:** GLPG3121 MAD
- **DRUG:** Placebo MAD

## Key facts

- **NCT ID:** NCT03899909
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-29
- **Primary completion:** 2019-06-03
- **Final completion:** 2019-06-03
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2019-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03899909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03899909, "A Study to Evaluate the Effects of a Single and Multiple Oral Doses of GLPG3121 in Adult, Healthy, Male Subjects". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03899909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*